Visit-to-Visit Blood Pressure Variability and Cardiovascular Death in the Systolic Hypertension in the Elderly Program

Journal of Clinical Hypertension

Volumn 16, Issue 1, 2014, Pages 34-40

  Kostis, John B ^a   Sedjro, Jeanine E ^a   Cabrera, Javier ^a,b   Cosgrove, Nora M ^a   Pantazopoulos, John S ^a   Kostis, William J ^c   Pressel, Sara L ^d   Davis, Barry R ^d  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE VARIABILITY; BODY MASS; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SMOKING; VISIT TO VISIT BLOOD PRESSURE VARIABILITY;

AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHLORTHALIDONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; OFFICE VISITS; PATIENT COMPLIANCE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84892368912     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12230     Document Type: Article

References (37)

1. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
2. Czernichow S, Zanchetti A, Turnbull F, et al. Blood Pressure Lowering Treatment Trialists' Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens. 2011;29:4-16.
3. Staessen JA, Wang JG, Thijs L, Fagard R. Overview of the outcome trials in older patients with isolated systolic hypertension. J Hum Hypertens. 1999;13:859-863.
4. Bejan-Angoulvant T, Saadatian-Elahi M, Wright JM, et al. Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials. J Hypertens. 2010;28:1366-1372.
5. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
6. Mancia G, De Backer G, Dominiczak A, et al. European Society of Hypertension; European Society of Cardiology. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press. 2007;16:135-232.
7. Khan NA, Hemmelgarn B, Herman RJ, et al. Canadian Hypertension Education Program. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol. 2009;25:287-298.
8. Hypertension: the clinical management of primary hypertension in adults: update of clinical guidelines 18 and 34 [internet]. National Clinical Guideline Centre (UK). London: Royal College of Physicians (UK); 2011 August National Institute for Health and Clinical Excellence: Guidance.
9. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF Task Force. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2011;123:2434-2506.
10. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375:895-905.
11. Muntner P, Shimbo D, Tonelli M, et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57:160-166.
12. Di Iorio B, Pota A, Sirico ML, et al. Blood pressure variability and outcomes in chronic kidney disease. Nephrol Dial Transplant. 2012;27:4404-4410.
13. Shimbo D, Newman JD, Aragaki AK, et al. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women's Health Initiative. Hypertension. 2012;60:625-630.
14. Shan ZZ, Dai SM, Su DF. Arterial baroreflex deficit induced organ damage in sinoaortic denervated rats. J Cardiovasc Pharmacol. 2001;38:427-437.
15. Kawabe H, Kanda T, Hirose H, Saito I. Variability of home blood pressure measurements between first and second measurements on one occasion, and factors related to variability. Clin Exp Hypertens. 2012;34:237-242.
16. Pavek K, Taube A. Personality characteristics influencing determinacy of day and night blood pressure and heart rate. Blood Press. 2009;18:30-35.
17. Kawai T, Ohishi M, Ito N, et al. Alteration of vascular function is an important factor in the correlation between visit-to-visit blood pressure variability and cardiovascular disease. J Hypertens. 2013;31:1387-1395.
18. Schillaci G, Bilo G, Pucci G, et al. Relationship between short-term blood pressure variability and large-artery stiffness in human hypertension: findings from 2 large databases. Hypertension. 2012;60:369-377.
19. Mancia G. Prognostic value of long-term blood pressure variability: the evidence is growing. Hypertension. 2011;57:141-143.
20. The Dutch TIA Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med. 1991;325:1261-1266.
21. Muntner P, Levitan EB, Joyce C, et al. Association between antihypertensive medication adherence and visit-to-visit variability of blood pressure. J Clin Hypertens. 2013;15:112-117.
22. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the systolic hypertension in the elderly program (SHEP) JAMA. 1991;265:3255-3264.
23. Kostis JB, Cabrera J, Cheng JQ, et al. Association between chlorthalidone treatment of systolic hypertension and long-term survival. JAMA. 2011;306:2588-2593.
24. Kostis JB, Davis BR, Cutler J, et al. SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212-216.
25. Wahba G. Smoothing noisy data with spline functions. Numer Math. 1975;24:383-393.
26. Wahba G. Spline bases, regularization, and generalized cross validation for solving approximation problems with large quantities. Proceedings of the International Conference on Approximation Theory in honour of George Lorenz. 1980;905-912.
27. Howard SC, Rothwell PM. Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke. Cerebrovasc Dis. 2009;28:331-340.
28. Dawson SL, Manktelow BN, Robinson TG, et al. Which parameters of beat-to-beat blood pressure and variability best predict early outcome after acute ischemic stroke? Stroke. 2000;31:463-468.
29. James GD, Pickering TG, Yee LS, et al. The reproducibility of average ambulatory, home and clinic pressures. Hypertension. 1988;11:545-549.
30. Eguchi K, Hoshide S, Schwartz JE, et al. Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension. Am J Hypertens. 2012;25:962-968.
31. Hsieh YT, Tu ST, Cho TJ, et al. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5.5-year prospective analysis. Eur J Clin Invest. 2012;42:245-253.
32. Tozawa M, Iseki K, Yoshi S, Fukiyama K. Blood pressure variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant. 1999;14:1976-1981.
33. Khattar RS, Swales JD, Banfield A, et al. Prediction of coronary and cerebrovascular morbidity and mortality by direct continuous ambulatory blood pressure monitoring in essential hypertension. Circulation. 1999;100:1071-1076.
34. Timmers HJLM, Buskers FGM, Wieling W, et al. Long-term effects of unilateral carotid endarterectomy on arterial baroreflex function. Clin Auton Res. 2004;14:72-79.
35. Eto M, Toba K, Akishita M, et al. Reduced endothelial vasomotor function and enhanced neointi- mal formation after vascular injury in a rat model of blood pressure liability. Hypertens Res. 2003;26:991-998.
36. Diaz KM, Veerabhadrappa P, Kashem MA, et al. Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans. Hypertens Res. 2012;35:55-61.
37. Okada H, Fukui M, Tanaka M, et al. Visit-to-visit blood pressure variability is a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Care. 2013;36:1908-1912.